Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial

NCT06363734 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer
EGFR Activating Mutation
Cell Cycle Deregulation
EGFR-TKI Resistant Mutation

Interventions

DRUG: Osimertinib plus Dalpiciclib

Sponsor

Tianjin Medical University Cancer Institute and Hospital